雷贝拉唑四联疗法对幽门螺杆菌阳性慢性胃炎患者COX-2、E-cadherin的影响

目的 探究雷贝拉唑四联疗法对幽门螺杆菌(Hp)阳性慢性胃炎患者环氧化酶-2(COX-2)、钙粘附蛋白E(E-cadherin)的影响.方法 选取我院2018年9月至2019年9月收治的120例Hp阳性慢性胃炎患者,以数字随机表法将其分为观察组(n=60,雷贝拉唑四联疗法)和对照组(n=60,常规四联疗法).比较两组的治...

Effect of rabeprazole quadruple therapy on COX-2 and E-cadherin in patients with Helicobacter pylori positive and chronic gastritis

Objective To explore the effect of rabeprazole quadruple therapy on cyclooxygenase-2(COX-2)and E-cadherin(E-cadherin)in patients with Helicobacter pylori(Hp)positive and chronic gastritis.Methods A total of 120 patients with Hp positive and chronic gastritis admitted in our hospital from September 2018 to September 2019 were divided into observation group(n=60,rabeprazole quadruple therapy)and control group(n=60,conventional quadruple therapy)by digital random table method.The therapeutic effects of the two groups were compared.Results After treatment,COX-2,E-cadherin,serum MIF and MMP-9 levels in the observation group were significantly lower than those in the control group(P<0.05).The Hp eradication rate in the observation group was 96.67%,which was significantly higher than 83.33%in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Rabeprazole quadruple therapy for patients with Hp positive and chronic gastritis has higher application value,it can improve the Hp eradication rate,down-regulate the levels of COX-2,E-cadherin,MIF,MMP-9,and no increase in adverse reactions.